Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.77 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21227710 | 0.79 | BRD4 (0.70) | BRD4TP53MAPTALDH1A1LMNA | |
| SCHEMBL27249468 | 0.76 | KDM4E (0.61) | BRD4SHMT2ALDH1A1LMNAGAA | |
| SCHEMBL17754063 | 0.75 | BRD4 (0.71) | BRD4TP53MAPTALDH1A1LMNA | |
| SCHEMBL22872873 | 0.74 | BRD4 (0.44) | BRD4SHMT2ALDH1A1PKMMEN1 | |
| SCHEMBL13591317 | 0.73 | BRD4 (0.67) | BRD4ALDH1A1POLBPKMMEN1 | |
| SCHEMBL19276665 | 0.72 | SMN1; SMN2 (0.63) | BRD4SHMT2ALDH1A1GAAMEN1 | |
| SCHEMBL18901199 | 0.72 | ROCK2 (0.69) | MAPTALDH1A1LMNAKDM4E | |
| SCHEMBL2736515 | 0.72 | BRD4 (0.66) | BRD4ALDH1A1POLBPKMKMT2A | |
| SCHEMBL2736514 | 0.72 | BRD4 (0.66) | BRD4ALDH1A1LMNAPOLBGAA | |
| SCHEMBL14284673 | 0.72 | USP2 (0.59) | MAPTALDH1A1LMNAGAAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-01-14 | — | — | US | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773085-B2 | Methods and compounds for treating disorders | VHL, TFEB, BECN1 | BRD4 57/4885SHMT2 1471/4885TP53 218/4885 |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | BRD4 57/4885SHMT2 1471/4885TP53 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.